The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation

  • Authors:
    • Weijin Sheng
    • Jianhua Gong
    • Min Jiang
    • Yongsu Zhen
  • View Affiliations

  • Published online on: October 23, 2017     https://doi.org/10.3892/or.2017.6053
  • Pages:3507-3514
0

Abstract

Previously it was shown that the recombinant EGFR/CD13 bi-targeted fusion protein ER(Fv)‑LDP-NGR which consists of an anti‑EGFR scFv antibody fragment, a tri‑cyclic NGR peptide, and a lidamycin-derived apoprotein, inhibited the proliferation of cancer cells and markedly suppressed tumor growth of breast carcinoma MCF-7 xenografts in athymic mice. This study investigated the mechanism of action of the fusion protein. Human breast cancer MCF-7 cells, lung adenocarcinoma A549 cells, and microvascular endothelial HMEC‑1 cells were used for a series of assays and determinations. ER(Fv)‑LDP-NGR downregulated the transcription and expression of the target proteins EGFR and CD13, and interfered with the intracellular EGFR signaling pathway, cell cycle signaling pathway and apoptotic pathway. It induced apoptosis, inhibited proliferation, caused cell cycle G2/M phase arrest, and suppressed cell migration. Accompanied by weakening the capability to degrade extracellular matrix, ER(Fv)‑LDP-NGR depressed the invasion capacity of cancer cells. In addition, ER(Fv)‑LDP-NGR prevented microvascular endothelial cells from tube formation, which is closely related to angiogenesis. In conclusion, the EGFR/CD13 bi-targeted fusion protein ER(Fv)‑LDP-NGR displays multi-functional characteristics, acting on both cancer cells and endothelial cells. It might be an effective agent for targeted cancer therapy.

Related Articles

Journal Cover

December 2017
Volume 38 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

2016 Impact Factor: 2.662
Ranked #31/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sheng, W., Gong, J., Jiang, M., & Zhen, Y. (2017). The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation. Oncology Reports, 38, 3507-3514. https://doi.org/10.3892/or.2017.6053
MLA
Sheng, W., Gong, J., Jiang, M., Zhen, Y."The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation". Oncology Reports 38.6 (2017): 3507-3514.
Chicago
Sheng, W., Gong, J., Jiang, M., Zhen, Y."The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation". Oncology Reports 38, no. 6 (2017): 3507-3514. https://doi.org/10.3892/or.2017.6053